Heart safety check for experimental drug varegacestat

NCT ID NCT06855264

Completed Knowledge-focused Sponsor: Immunome, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed phase 1 study tested whether a single dose of varegacestat changes heart rhythm in 32 healthy adults. Participants received varegacestat, a placebo, and a control drug (moxifloxacin) in random order. The main goal was to measure any effects on the heart's electrical activity. Results will help decide if varegacestat is safe enough for further testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: varegacestat
What this could lead to: If this study shows varegacestat does not affect heart rhythm, it could support further testing of the drug for other conditions.
What could go wrong: This is a very early, small study in healthy volunteers, not patients. It only looks at heart safety after a single dose, so it cannot predict long-term effects or whether the drug works for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER

Contacts and locations

Show contact details

Locations

Celerion

Tempe, Arizona, 85289, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.